New Framework Boosts Actionable Genomic Testing in Cancer

Publication Title: A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling.

Summary

J Natl Compr Canc Netw
February 2026
Read Full Publication

Question: This study aimed to evaluate a new classification system called the Yale Molecular Alteration Taxonomy for Real-World Individualized Treatments (Y-MATRIX). The researchers applied Y-MATRIX to assess the clinical actionability of broad genomic profiling (BGP) results in patients with advanced non–small cell lung cancer (aNSCLC) from 2017 to 2023. The objective was to examine how molecular findings influenced treatment decisions and changed over time as targeted therapies became available.
Why it Matters: Broad genomic profiling is increasingly used in cancer care to identify genetic alterations that can guide targeted therapies. However, interpreting these complex molecular results in real-world settings remains challenging, especially as treatment guidelines and drug approvals evolve. This study addresses this gap by introducing Y-MATRIX, a framework that classifies molecular findings based on their clinical actionability. Understanding these classifications helps oncologists make informed treatment decisions, ensures patients receive appropriate care, and can reduce the cost burden associated with inappropriate off-label drug use. This research is particularly significant for improving precision oncology and advancing the development of targeted therapies.
Methods: The researchers developed Y-MATRIX to classify molecular alterations into six categories based on FDA approvals and NCCN guidelines. Categories ranged from first-line actionable alterations (category A) to findings with no actionability (category E/X). Using the Flatiron Health-Foundation Medicine Clinico-Genomic Database, they analyzed genomic data from 8,717 patients diagnosed with aNSCLC between 2017 and 2023. Molecular results were assessed against yearly updates in guidelines and approvals to capture changes in actionability over time.
Key Findings: The study found that the proportion of patients with actionable genomic alterations increased significantly from 2017 to 2023. Category A (first-line therapies) rose slightly from 15.8% to 18.4%, while category B (later-line therapies) increased from 0% to 15.2%. Meanwhile, the proportion of patients with non-actionable findings (categories E/X) dropped from 63.1% to 27.1%. Factors such as younger age, nonsmoking status, and nonsquamous tumor histology were associated with higher likelihoods of actionable alterations. The results highlighted the growing impact of targeted therapy development and guideline changes on clinical practice.
Implications: Y-MATRIX provides a practical tool for analyzing molecular testing results and guiding precision oncology. By demonstrating the increasing availability of actionable findings, the study underscores the value of broad genomic profiling in tailoring cancer treatments. This framework can improve the understanding of real-world treatment patterns, highlight areas of uncertainty, and support the development of new targeted therapies. It also offers insights into patient populations that may benefit most from molecular testing, informing clinical and policy decisions.
Next Steps: The authors suggest applying Y-MATRIX to other cancer types to explore its generalizability and utility. Future research should investigate the clinical outcomes and cost-effectiveness of treatments based on Y-MATRIX classifications. Additional studies could also focus on refining the taxonomy to account for emerging biomarkers and new therapeutic options.
Funding Information: This research was supported by the National Cancer Institute of the National Institutes of Health (awards 5R01CA280359-02 and T32CA233414). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Full Citation

Wang X, Long JB, Rothen J, Huang S, Soulos PR, Goldberg SB, Robinson TJ, Ma S, Mamtani R, Presley CJ, Wang SY, Kunst N, Gross CP, Dinan MA. A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. J Natl Compr Canc Netw 2026, 1-6. PMID: 41698347, DOI: 10.6004/jnccn.2025.7131.